{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:01:34Z","timestamp":1791813694889,"version":"4.3.4"},"reference-count":98,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetes mellitus (DM) poses an increasingly high global health burden nowadays, while in adults, chronic kidney disease (CKD) associated with DM impacts 20\u201340% of those with the condition. Effective management of CKD in patients with diabetes necessitates a comprehensive, multidisciplinary approach. Numerous factors, including glomerular hyperfiltration, oxidative stress, inflammation, and hypoxia are linked to the advancement of diabetic kidney disease (DKD). Currently, no specific treatment for DKD has been established, prompting extensive exploration of new approaches. Renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter 2 inhibitors have demonstrated renoprotective effects in various human clinical trials. Additionally, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor antagonists have been reported as effective in managing DKD, while new therapeutic candidates are also under investigation, such as soluble guanylate cyclase activators and aldosterone synthase inhibitors. Recent evidence has shown that treating diabetic nephropathy by reducing albuminuria levels and retarding its progression is a complex skill. The purpose of this review is to support the impressive results that appear in reducing albuminuria and the progression of diabetic nephropathy with early and intensive combination treatment compared to the recently emerged conventional monotherapy, with agents that act on different pathophysiological mechanisms.<\/jats:p>","DOI":"10.3390\/ijms26178224","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:10:36Z","timestamp":1756080636000},"page":"8224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?"],"prefix":"10.3390","volume":"26","author":[{"given":"Georgia","family":"Doumani","sequence":"first","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-6306","authenticated-orcid":false,"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Vordoni","sequence":"additional","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6287-4160","authenticated-orcid":false,"given":"Vasileios","family":"Thymis","sequence":"additional","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Liapis","sequence":"additional","affiliation":[{"name":"1st Department of Pathology Medical School, National and Kapodistrian University of Athens, Laikon Hospital, 11627 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0575-3762","authenticated-orcid":false,"given":"Despina","family":"Smirloglou","sequence":"additional","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-7575","authenticated-orcid":false,"given":"Rigas G.","family":"Kalaitzidis","sequence":"additional","affiliation":[{"name":"Center for Nephrology \u201cG. Papadakis\u201d, General Hospital of Nikaia-Piraeus \u201cAg. Panteleimon\u201d, 18454 Nikaia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_5","first-page":"102","article-title":"Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria","volume":"18","author":"Viejo","year":"2022","journal-title":"Eur. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0115701611361265250211062540","article-title":"Efficacy of Dapagliflozin and Telmisartan Combination Therapy in Reducing Albuminuria and Inflammatory Markers in Diabetic Nephropathy: A Prospective Observational Study","volume":"23","author":"Chauhan","year":"2025","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nep.13182","article-title":"Clinical and pathological factors associated with progression of diabetic nephropathy","volume":"22","author":"Liang","year":"2017","journal-title":"Nephrology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on Diabetic Nephropathy: Core Curriculum 2018","volume":"71","author":"Umanath","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","author":"Foundation","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc24-S004","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards Care Diabetes\u20142024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic Classification of Diabetic Nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","first-page":"CD006257","article-title":"Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease","volume":"4","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"(2003). The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics. Control. Clin. Trials., 24, 442\u2013461.","DOI":"10.1016\/S0197-2456(03)00028-X"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/j.ackd.2021.11.001","article-title":"Treatment of Diabetic Nephropathy: Changing Landscapes and New Horizons","volume":"28","author":"Thakar","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Parving, H.H., and Rossing, P. (2020). The History of Prevention and Treatment of Diabetic Nephropathy. Unveiling Diabetes-Historical Milestones in Diabetology, S. Karger AG.","DOI":"10.1159\/000506547"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","article-title":"The effect of RAAS blockade on the progression of diabetic nephropathy","volume":"10","author":"Roscioni","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000810","DOI":"10.1161\/JAHA.114.000810","article-title":"The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade with Olmesartan Treatment Are Sustained After Study Discontinuation","volume":"3","author":"Menne","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3904\/kjim.2016.219","article-title":"Treatment of diabetic kidney disease: Current and future targets","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.113.007071","article-title":"Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration","volume":"129","author":"Stanton","year":"2014","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","article-title":"Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?","volume":"38","author":"Cherney","year":"2014","journal-title":"Can. J. Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why Do SGLT2 Inhibitors Inhibit Only 30\u201350% of Renal Glucose Reabsorption in Humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose Transporters in Human Renal Proximal Tubular Cells Isolated from the Urine of Patients with Non\u2013Insulin-Dependent Diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Patel, D.M., Bose, M., and Cooper, M.E. (2020). Glucose and Blood Pressure-Dependent Pathways\u2013The Progression of Diabetic Kidney Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062218"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.111.186866","article-title":"Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats","volume":"340","author":"Liu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db\/db Mice","volume":"18","author":"Park","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Thomas, M.C. (2017). The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab., 43.","DOI":"10.1016\/S1262-3636(17)30069-1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: A randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats","volume":"21","author":"Yu","year":"2003","journal-title":"J. Hypertens."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Correction in Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000337929","article-title":"Exenatide Reduces Urinary Transforming Growth Factor-\u03b21 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria","volume":"35","author":"Zhang","year":"2012","journal-title":"Kidney Blood Press Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Estrela","year":"2018","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dutzmann, J., Musmann, R.-J., Haertl\u00e9, M., Daniel, J.-M., Sonnenschein, K., Sch\u00e4fer, A., Kolkhof, P., Bauersachs, J., and Sedding, D.G. (2017). The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184888"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., and Dong, B. (2023). Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1125693"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Krishnan, S., Kraehling, J., Eitner, F., B\u00e9nardeau, A., and Sandner, P. (2018). The Impact of the Nitric Oxide (NO)\/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061712"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ott, I.M., Alter, M.L., von Websky, K., Kretschmer, A., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K., Raila, J., Henze, A., and Stasch, J.-P. (2012). Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042623"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1111\/bph.15586","article-title":"Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney","volume":"179","author":"Stehle","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: A randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-016-0290-z","article-title":"Soluble Guanylate Cyclase Stimulators: A Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?","volume":"13","author":"Dubin","year":"2016","journal-title":"Curr. Heart Fail Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"28263","DOI":"10.1073\/pnas.2000466117","article-title":"Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP\/NF-\u03baB\/NLRP3 inflammasome circuit","volume":"117","author":"Casulleras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00210-021-02149-4","article-title":"Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease","volume":"394","author":"Kahnert","year":"2021","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Vodo\u0161ek Hojs, N., Bevc, S., Ekart, R., and Hojs, R. (2020). Oxidative Stress Markers in Chronic Kidney Disease with Emphasis on Diabetic Nephropathy. Antioxidants, 9.","DOI":"10.3390\/antiox9100925"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Sandner, P., Zimmer, D.P., Milne, G.T., Follmann, M., Hobbs, A., and Stasch, J.P. (2018). Soluble Guanylate Cyclase Stimulators and Activators. Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications, Springer.","DOI":"10.1007\/164_2018_197"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.115.230706","article-title":"A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat","volume":"356","author":"Harrison","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Czirok, S., Fang, L., Radovits, T., Szab\u00f3, G., Sz\u00e9n\u00e1si, G., Rosivall, L., Merkely, B., and K\u00f6k\u00e9ny, G. (2017). Cinaciguat ameliorates glomerular damage by reducing ERK1\/2 activity and TGF-\u00df expression in type-1 diabetic rats. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-10125-3"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/bph.15425","article-title":"Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice","volume":"179","author":"Harloff","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kraehling, J.R., Benardeau, A., Schomber, T., Popp, L., Vienenkoetter, J., Ellinger-Ziegelbauer, H., Pavkovic, M., Hartmann, E., Siudak, K., and Freyberger, A. (2023). The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713226"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.122.001423","article-title":"The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease","volume":"384","author":"Reinhart","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of Avenciguat on Albuminuria in Patients with CKD","volume":"35","author":"Heerspink","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E362","DOI":"10.1152\/ajpendo.00254.2024","article-title":"A novel soluble guanylate cyclase activator, avenciguat, in combination with empagliflozin, protects against renal and hepatic injury in diabetic db\/db mice","volume":"328","author":"Sharma","year":"2025","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1220095","DOI":"10.3389\/fcvm.2023.1220095","article-title":"Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase","volume":"10","author":"Sharma","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100992","DOI":"10.1016\/j.xcrm.2023.100992","article-title":"Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution","volume":"4","author":"Balzer","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hu, L., Chen, Y., Zhou, X., Hoek, M., Cox, J., Lin, K., Liu, Y., Blumenschein, W., Grein, J., and Swaminath, G. (2022). Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0261000"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/dom.15099","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.23876\/j.krcp.21.251","article-title":"Exploring molecular targets in diabetic kidney disease","volume":"41","author":"Maruno","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Shrestha, A., Che, R.C., and Zhang, A.H. (2019). Role of Aldosterone in Renal Fibrosis. Renal Fibrosis: Mechanisms and Therapies, Springer.","DOI":"10.1007\/978-981-13-8871-2_15"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cpdd.1371","article-title":"Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function","volume":"13","author":"Freeman","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: A randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-D\u00edaz, I., Martos, N., Llorens-Cebri\u00e0, C., \u00c1lvarez, F.J., Bedard, P.W., Vergara, A., Jacobs-Cach\u00e1, C., and Soler, M.J. (2023). Endothelin Receptor Antagonists in Kidney Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043427"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","article-title":"The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease","volume":"97","author":"Hasegawa","year":"2020","journal-title":"Kidney Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:21Z","timestamp":1760034921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":98,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178224"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178224","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,24]]}}}